Patrick Deegan

List of Publications by Year
in descending order

19	768	933447 10	839539 18
papers	citations	h-index	g-index

19	19	19	1225
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. Journal of Medical Genetics, 2017, 54, 288-296.	3.2	262
2	The glucocerobrosidase E326K variant predisposes to Parkinson's disease, but does not cause Gaucher's disease. Movement Disorders, 2013, 28, 232-236.	3.9	121
3	Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis. British Journal of Haematology, 2009, 147, 561-570.	2.5	97
4	Gaucher Disease in Bone: From Pathophysiology to Practice. Journal of Bone and Mineral Research, 2019, 34, 996-1013.	2.8	94
5	Exploring the patient journey to diagnosis of Gaucher disease from the perspective of 212 patients with Gaucher disease and 16 Gaucher expert physicians. Molecular Genetics and Metabolism, 2017, 122, 122-129.	1.1	51
6	Demographics and patient characteristics of 1209 patients with Gaucher disease: Descriptive analysis from the Gaucher Outcome Survey (GOS). American Journal of Hematology, 2018, 93, 205-212.	4.1	44
7	Reported outcomes of 453 pregnancies in patients with Gaucher disease: An analysis from the Gaucher outcome survey. Blood Cells, Molecules, and Diseases, 2018, 68, 226-231.	1.4	20
8	Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey. Molecular Genetics and Metabolism Reports, 2018, 14, 73-79.	1.1	18
9	Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy. Heart, 2019, 105, 1825-1831.	2.9	15
10	The motor and cognitive features of Parkinsonâ€™s disease in patients with concurrent Gaucher disease over 2 years: a case series. Journal of Neurology, 2018, 265, 1789-1794.	3.6	11
11	In-depth phenotyping for clinical stratification of Gaucher disease. Orphanet Journal of Rare Diseases, 2021, 16, 431.	2.7	11
12	A randomised controlled trial evaluating arrhythmia burden, risk of sudden cardiac death and stroke in patients with Fabry disease: the role of implantable loop recorders (RaILRoAD) compared with current standard practice. Trials, 2019, 20, 314.	1.6	6
13	The International Collaborative Gaucher Group GRAF (Gaucher Risk Assessment for Fracture) score: a composite risk score for assessing adult fracture risk in imiglucerase-treated Gaucher disease type 1 patients. Orphanet Journal of Rare Diseases, 2021, 16, 92.	2.7	5
14	Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom. PLoS ONE, 2018, 13, e0191945.	2.5	4
15	Improving the quantitative classification of Erlenmeyer flask deformities. Skeletal Radiology, 2021, 50, 361-369.	2.0	3
16	Avascular Necrosis in Untreated Patients with Type 1 Gaucher Disease.. Blood, 2009, 114, 1353-1353.	1.4	3
17	MO035HISTORICAL CONTROL ANALYSIS DEMONSTRATES SUPERIOR REDUCTION OF PLASMA GLOBOTRIAOSYLCERAMIDE BY VENGLUSTAT COMPARED WITH PLACEBO OR AGALSIDASE BETA IN CLASSIC FABRY DISEASE PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	2
18	P0062GLUCOSYLCERAMIDE SYNTHASE INHIBITION WITH VENGLUSTAT IN CLASSIC FABRY DISEASE PATIENTS LEADS TO PROGRESSIVE REDUCTION OF ENDOTHELIAL CELL GLOBOTRIAOSYLCERAMIDE INCLUSION VOLUME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	1

#	Article	IF	Citations
19	Determinants of Persisting Thrombocytopenia In Patients with Type 1 Gaucher Disease Treated with Alglucerase/Imiglucerase for 4â€“5 Years. Blood, 2010, 116, 4719-4719.	1.4	0